Stockwinners Market Radar for August 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:20 EDT Cathie Wood's ARK Investment bought 170K shares of Adaptive Biotechnologies

20:18 EDT Cathie Wood's ARK Investment bought 658K shares of UiPath

19:52 EDT Axonics exec sells $920.7K in common stock - In a regulatory filing, Axonics disclosed that its Chief Commercial Officer Alfred Ford sold 14.7K shares of common stock on August 15th in a total transaction size of $920.7K.

19:14 EDT Beauty Health chairman buys $362.4K in common stock - In a regulatory filing, Beauty Health disclosed that its chairman Brent Saunters bought 59.4K shares of common stock on August 16th in a total transaction size of $362.4K.

19:01 EDT MediciNova's abstact on MN-166 in glioblastoma selected for SNO presentation - MediciNova "announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166, or ibudilast, in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada. The poster will be presented by MediciNova's collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center."

18:30 EDT Marqeta director Linville acquires 34,000 class A shares - In a regulatory filing, Marqeta director Judson Linville disclosed the purchase of 34,000 class A common shares of the company on August 15 at a price of $5.8645 per share.

17:26 EDT Amsterdam based payments processor Adyen falls over 35% amid costs, competition - Shares of Amsterdam based payments processor Adyen (ADYEY) closed down over 35% or approximately $5.50 per share, to close at $9.86 on Thursday. The European payment processor reported IH EBITDA margin was 43% down from 59% in 1H22. Adyen management noted that hiring costs pinched margins and revenue growth was slower in North America. Adyen's rivals in the include Stripe, Braintree, Fiserv (FI) and PayPal (PYPL).

17:19 EDT Staar Surgical to replace Urstadt Biddle in S&P 600 at open on 8/22 - Regency Centers (REG) will acquire Urstadt Biddle Properties (UBA) in a transaction expected to close soon pending final closing conditions.

17:15 EDT Nxu Inc announces strategic focus on EV charging infrastructure - Nxu "announced a strategic shift to focus on its EV charging infrastructure technology. Nxu's differentiated charging and energy storage technology has the potential to expedite the vision for our collective electrified future, so the immediate focus of the Company is aimed at concentrating and leveraging the resources and efforts that advance the realization of that vision. This re-sequencing of our product roadmap to prioritize our charging technology puts the Company on the path to near-term revenue generation with a unique and highly competitive solution to address the worldwide EV charging station shortage. With the ultimate goal of creating shareholder value and achieving profitability, the Company intends to leverage the favorable economics on its initial deployment to rapidly scale. Nxu is undertaking numerous cost-saving measures to decrease operating expenses through consolidation of vendors and product programs that do not support the core focus of Nxu. Amid greater economic and industry headwinds, additional cost-saving measures must be made through a furlough."

17:06 EDT CACI awarded $414.13M Air Force task order - CACI was awarded a $414.13M cost-plus-fixed-fee, level of effort term task order for complete spectrum of life cycle software and systems engineering for mission and functional requirements. This order provides for the performance, research, and gathering of data and information processing capabilities to improve battlespace awareness and data for decision making. Work is expected to be completed by Aug. 17, 2028. This contract was a competitive acquisition and one offer was received. FY23 research, development, test and evaluation funds in the amount of $250,000; FY23 procurement funds in the amount of $250,000 and FY23 operations and maintenance funds in the amount of $1.78M, are being obligated at time of award. The Air Force Research Laboratory is the contracting activity.

17:05 EDT Alpha Tau's Alpha DaRT shows safety and efficacy in multiple trials - Alpha Tau reported initial long-term safety and tumor control outcomes of alpha-radiation cancer therapy Alpha DaRT for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors across four prospective trials. Between February 2017 and December 2022, 81 lesions in 71 patients were treated with Alpha DaRT in four prospective feasibility trials whose objective was to assess early toxicity and tumor response outcomes. A complete response was observed in 89% of treated lesions, 10% demonstrated a partial response, and one patient was not evaluable. - Two-year local recurrence-free survival rate was 77%. 20% of patients developed treatment-related acute grade 2 toxicity such as dermatitis radiation, local pain at the treatment site or pruritus, which subsequently resolved with conservative treatment; there were no grade 3 or higher related acute toxicities. There was no grade 2 or higher late toxicities observed in this cohort, defined as toxicities occurring six months or later after Alpha DaRT treatment.

16:58 EDT Paylocity director sells $2.79M in common stock - In a regulatory filing, Paylocity disclosed that its director Steven Sarowitz sold 14.3K shares of common stock on August 16th in a total transaction size of $2.79M.

16:39 EDT Blue Foundry Bancorp announces 1.3M share stock repurchase program - Blue Foundry Bancorp announced that it has adopted a program to repurchase up to 1,268,382 shares of its common stock, which is approximately 5% of its outstanding common stock. This is the Company's third stock repurchase program since completing its mutual-to-stock conversion and related stock offering in July 2021. The Company's previous stock repurchase programs provided for a total of 4,187,376 shares to be repurchased. As of August 16 there were 250 shares remaining to be repurchased under the second plan. The third plan will commence immediately upon the completion of the second plan. The repurchase program permits shares to be repurchased in open market or private transactions, through block trades or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission. The timing and amount of any repurchases will depend on a number of factors, including the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company's financial performance. Open market purchases will be made in accordance with Rule 10b-18 of the Securities and Exchange Commission and other applicable legal requirements. The Company is not obligated to repurchase any particular number of shares or any shares in any specific time period. James D. Nesci, President and CEO of the Company, remarked that, "We are pleased to announce our third repurchase program. We believe that share repurchases are a prudent use of capital and are pleased to have the strong capital position that allows us the ability to purchase stock."

16:33 EDT Fitch revises Invitation Homes rating outlook to 'Positive' from 'Stable' - Invitation Homes announced that Fitch Ratings revised its rating outlook for the Company to 'Positive' from 'Stable' and affirmed the company's ratings, including the 'BBB' Long-Term Issuer Default Ratings. In its public announcement on the matter, Fitch cited its "positive outlook revision considers [the Company's] balance sheet and capital access strength" and noted that "such access positions the Company well for opportunistic transactions and cushion in addressing upcoming maturities. This is possible with Invitation Homes' relationships with builders, joint venture partnerships and capital recycling program that provide for a variety of funding avenues and future growth opportunities."

16:32 EDT Argan's APC receives notice to proceed for 264-MW power project in Ireland - Argan announced that its subsidiary, Atlantic Projects Company, received full notice to proceed on an engineering, procurement and construction services contract with GE Vernova for the Shannonbridge Power Project in County Offaly, Ireland. The Shannonbridge Project, an initiative of EirGrid and the Electricity Supply Board of Ireland, aims to enhance the region's power infrastructure and to ensure a reliable electricity supply during critical situations and emergencies. The power plant will feature eight GE LM2500XPRESS units, built with proven LM2500 aeroderivative gas turbine technology. APC and its U.S.-based sister company, Gemma Power Systems, will work on the project with GE Vernova and will oversee the entire project lifecycle, including design, procurement, construction and commissioning. With their combined expertise in engineering and construction, the APC/Gemma team will work collaboratively with all interested parties to achieve the targeted completion date of early 2024. Work commenced earlier this year under limited notices to proceed. "We understand the importance to Ireland of having a robust and reliable national power supply, especially during times of high demand," said Billy Nolan, Managing Director of APC. "With a 50-year global pedigree in providing power generation solutions, our experienced team is dedicated to executing this project with the utmost professionalism while adhering to safety and quality standards. The Shannonbridge Project is expected to serve as a vital resource to ensuring the security of the electricity supply when the country needs it."

16:21 EDT Express announces more actions to deliver $200M in annualized savings by 2025 - "We expect second quarter net sales and diluted loss per share to be within the ranges of our outlook. Net sales for the Express brand improved sequentially throughout the second quarter driven by the corrective actions we have taken to address imbalances in our women's assortment architecture. These results give us confidence that we will continue to see improvement in net sales for the Express brand in the back half of the year," said Tim Baxter, Chief Executive Officer. "Additionally, the integration of the Bonobos brand into our omnichannel platform and its performance are on track." "As we transform EXPR to create shareholder value, we are committed to driving long-term profitable growth and delivering positive free cash flow in our core Express business. We are conducting a comprehensive review of our business model to identify actions that we believe will meaningfully reduce pre-tax costs and enable a more efficient and effective organization. Today we are announcing a goal to deliver $150 million in annualized expense reductions by 2025 versus 2022 and have already identified and implemented $80 million for 2023 and $120 million for 2024. In addition, we are also aggressively pursuing at least $50 million in gross margin expansion opportunities by leveraging efficiencies in sourcing, production and the supply chain," continued Baxter. In May 2023, the Company announced it had identified and implemented $65 million of annualized cost reductions for fiscal 2023 versus fiscal 2022. Today the Company announced an additional $15 million of savings for a total of $80 million in annualized cost reductions identified and implemented for fiscal 2023. The annualized cost reductions of $120 million for fiscal 2024 include a workforce reduction which is expected to generate savings of approximately $30 million.

16:18 EDT Medical Properties Trust sells $105M of interest in asset-backed credit facility - Medical Properties Trust announced that it has sold $105M of its interest in Steward Health Care System's new syndicated asset-backed credit facility to a leading global asset manager with more than $100B in assets under management. "As we said during our recent quarterly update, this new ABL facility significantly enhanced Steward's available liquidity and flexibility at a time when its operations continue to perform well," said Edward K. Aldag, Jr., Chairman, President and CEO. "MPT's participation enabled Steward to close on this facility months ahead of maturity, removing market concerns around its ability to refinance. This prompt reduction in MPT's commitment to the facility reflects the Company's focus on reducing leverage as well as the continued strong level of participation interest from sophisticated third-party lenders."

16:15 EDT Kaival amends pact with Philip Morris for ENDS Products distribution - Kaival Brands (KAVL) Innovations Group announced that its wholly-owned subsidiary, Kaival Brands International has amended its agreement with Philip Morris Product a wholly owned affiliate of Philip Morris International (PM), for the development and distribution of electronic nicotine delivery system products in markets outside of the U.S. Eric Mosser, Chief Executive Officer of Kaival Brands, stated, "With more than a year of operational history for KBI and given the recent changes to regulations in international markets, it became clear that there were a number of opportunities to improve the terms of the original licensing agreement and reduce the burden of administering it. We are extremely pleased to reach an agreement that shall enable us to achieve our objectives. The revised licensing agreement simplifies the payment structure resulting in cost savings of approximately $2.7M for the Company over the lifetime of the license agreement. It also enables better predictability and forecasting for KBI and streamlines data reporting. Finally, we anticipate that the acceleration of royalty payments will be a net positive to our financial performance over the duration of the agreement." Under the terms of the amended agreement, the parties agreed to revise certain terms, which provide for, among other things, a fixed pricing structure with volume-driven increases and a recapture of non-recurring engineering costs by KBI. Accordingly, the Company expects a reconciliation payment of approximately $135,000. Furthermore, the Company projects approximately $300,000 in additional royalties to be earned through the end of 2023.

16:09 EDT Revolution Medicines publishes KRASG12C-selective inhibitors data in Science - Revolution Medicines announced the publication of a peer-reviewed research paper in Science. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from Memorial Sloan Kettering Cancer Center. The paper describes the Revolution Medicines tri-complex inhibitor approach to developing novel small molecules with high affinity and selectivity for the active state of mutant RAS, or RAS(ON), proteins that are common causes of human cancer and were previously considered undruggable. Specifically, it describes the creation of product-inspired, orally bioavailable small molecules, including the tool compound RMC-4998 and the clinical candidate RMC-6291. These compounds are shown to remodel the surface of the cellular chaperone cyclophilin A, or CYPA, to create a neomorphic interface with affinity for active KRAS and achieve high selectivity for mutant KRASG12C via covalent, irreversible binding to the cysteine residue in the active state of this variant RAS protein that often drives formation of lung and colorectal cancers. KRASG12C(ON) trapped in these tri-complexes is sterically blocked from interacting with downstream effectors that transmit cancer-causing signals. Both RMC-4998 and RMC-6291 inactivate oncogenic signaling in KRASG12C-dependent tumor cells and drive deep and durable tumor regressions in human xenograft models of these cancers.

16:08 EDT Keysight Technologies falls 5% to $142.56 after below-consensus guidance

16:01 EDT Bark authorizes repurchase of up to $7.5M of common shares - Bark announced that its Board of Directors has authorized the repurchase of up to $7.5 million of its common shares, the maximum amount set forth under the terms related to the Company's outstanding convertible notes. This decision reflects the Company's strong financial position, continued expansion into promising categories like consumables, and positive outlook on its future cash position. "We remain committed to delivering value to our shareholders and today's announcement is a testament to our healthy balance sheet and confidence in our ability to execute on our key initiatives," said Zahir Ibrahim, Chief Financial Officer. "While limited by the terms related to our convertible notes, which cap our share repurchase capacity to $7.5 million each calendar year, we have the opportunity to repurchase over 3% of our market capitalization at current share prices. Given our robust runway, we believe this is a strategic use of capital."

14:55 EDT CVS reaffirms outlook after 'partial termination' of California contract

14:53 EDT CVS says Blue Shield of California change not expected to impact 2023 outlook

13:26 EDT Hitek Global Inc trading resumes

12:34 EDT Able View completes combination with Hainan Manaslu Acquisition - Able View Global announced that it has completed its previously announced business combination with Hainan Manaslu Acquisition Corp, a publicly traded special purpose acquisition company. The business combination was approved at an extraordinary general meeting of HMAC's shareholders on August 2, 2023. Upon the closing of the business combination, HMAC and Able View Inc. each becomes a wholly owned subsidiary of Able View Global Inc. Beginning August 18, 2023, Able View's Class B ordinary shares and warrants will trade on the Nasdaq Capital Market under the ticker symbols "ABLV" and "ABLVW," respectively. Zhifan Zhou, CEO of HMAC commented, "We are excited to complete the Business Combination between HMAC and Able View. The HMAC team is honored to be part of this landmark occasion for Able View."

12:02 EDT Aditxt announces 1-for-40 reverse stock split - Aditxt will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on August 18, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on August 18, 2023, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the annual meeting held on August 16, 2023, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025604. As a result of the reverse stock split, every 40 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the Company will have approximately 190,319 shares of common stock issued and outstanding. The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's minimum bid price requirement.

12:00 EDT Wolfspeed falls -19.4% - Wolfspeed is down -19.4%, or -$10.30 to $42.87.

12:00 EDT Triumph Group rises 9.3% - Triumph Group is up 9.3%, or 78c to $9.14.

12:00 EDT Chegg rises 11.9% - Chegg is up 11.9%, or $1.14 to $10.66.

11:29 EDT Turkcell trading halted, news pending

10:33 EDT Roblox down 4% to $28.18 after cautious Bear Cave report

10:20 EDT DoorDash Canada, Staples Canada partner for delivery - DoorDash Canada and Staples Canada announced a new nationwide partnership, giving consumers convenient on-demand access to thousands of back-to-school and workplace essentials. Whether it's for the first year of elementary school or the first year of college, students can now get all the items on their supply list delivered same-day directly to their doorstep with DoorDash, and with $0 delivery fees on eligible orders with DashPass.

10:04 EDT SoundHound collaborates with Turkish mobility provider Togg - SoundHound AIannounced its advanced AI technology, including innovative Edge+Cloud connectivity, multiple language capabilities, and a custom-branded voice assistant, is live in a new line of smart vehicles from Turkish mobility provider, Togg. Launched in Q2 2023, Togg vehicles have been described as a "new living space" that will redefine mobility. As part of Togg's tech-forward vision to create a more user-centric experience, the mobility provider has collaborated with SoundHound to deliver a sophisticated, best-in-class voice AI.

10:00 EDT Caesars launches Caesars Racebook in New York - Caesars Entertainment announced that its horse racing account wagering app, Caesars Racebook, is now live in New York State. Horse racing fans in the Empire State can now enjoy pari-mutuel wagering on premier horse racing content from more than 300 tracks around the world, all tied to Caesars Rewards, the gaming industry's leading loyalty program. Caesars Racebook's debut in New York builds on the success of recent launches in sixteen states, including California, Colorado, Florida, Indiana, Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Montana, North Dakota, Ohio, Oregon, Pennsylvania, Washington, and Wyoming. Powered by NYRA Bets, Caesars Racebook provides bettors with a secure, state-of-the-art platform that allows customers to conveniently watch and wager on the world's best horse racing. Caesars Racebook is now available in New York on iOS, Android and desktop.

10:00 EDT Wolfspeed falls -18.1% - Wolfspeed is down -18.1%, or -$9.65 to $43.52.

10:00 EDT Tencent Music rises 7.2% - Tencent Music is up 7.2%, or 46c to $6.86.

10:00 EDT Super Group rises 18.4% - Super Group is up 18.4%, or 54c to $3.47.

09:47 EDT LL Flooring falls -9.7% - LL Flooring is down -9.7%, or -42c to $3.90.

09:47 EDT Hawaiian Electric falls -25.2% - Hawaiian Electric is down -25.2%, or -$3.58 to $10.63.

09:47 EDT Philips rises 5.7% - Philips is up 5.7%, or $1.21 to $22.59.

09:42 EDT Hawaiian Electric trading resumes

09:38 EDT Helius Medical Technologies Inc trading resumes

09:33 EDT Helius Medical Technologies Inc trading halted, volatility trading pause

09:25 EDT ESS names Jeff Loebbaka Chief Commercial Officer - ESS Tech announced the expansion of its executive leadership team. Jeff Loebbaka has been named Chief Commercial Officer, adding significant depth to ESS leadership as the company continues to grow its global ootprint and deliver long-duration energy storage solutions to customers worldwide. "Jeff brings a wealth of experience growing emerging clean technology companies into global enterprises," saidEric Dresselhuys, CEO of ESS. "His strategic vision will expand ESS' capabilities to deliver long-duration energy storage solutions to global markets and catalyze the clean energy future." Loebbaka has held a number of executive leadership positions in technology and clean energy companies including AMP Robotics, Spruce Financial and Enphase Energy. He holds a B.S. in mechanical engineering from the University of Illinois Urbana-Champaign and an M.B.A. from the Kellogg School at Northwestern University. "It is now clear that long-duration energy storage is foundational to a decarbonized energy system. ESS has the right technology and right team to meet skyrocketing demand for this critical solution," said Loebbaka. "I am excited to join ESS

09:17 EDT Illumina opens Solutions Center in India - Illumina opened a new office and Illumina Solutions Center in Bengaluru, India. Illumina's expansion comes after 16 years of working with the company's channel partner in India, Premas Life Sciences. Now with its own permanent facility, Illumina will continue to collaborate with Premas to grow the genomics market in India. Illumina employs over 30 people in India, in sales, operations, marketing, government relations, and human resources, and more hiring is expected as Illumina moves to scale operations there. The business is led by Abhishek Gupta, country manager. The new Illumina Solutions Center features a laboratory housing NGS and array technologies, and resourced with field applications and service engineers to offer Illumina's partners and customers genomics capabilities.

09:15 EDT Digital World Acquisition urges stockholders to vote for extension - Digital World Acquisition Corp. announced today that the special meeting of stockholders, which was originally scheduled for August 17, 2023, is being postponed to 10:00 a.m. Eastern Time on September 5, 2023. The Special Meeting is for stockholders to consider amending the Company's amended and restated certificate of incorporation as further amended on November 22, 2022, to extend, upon the approval by the Company's board of directors, the period of time for the Company to consummate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving the Company and one or more businesses, to cease its operations if it fails to complete such business combination, and to redeem or repurchase 100% of the Company's Class A common stock included as part of the units sold in the Company's initial public offering that was consummated on September 8, 2021 up to four times, each by an additional three months, for an aggregate of 12 additional months or such earlier date as determined by the Board. The record date for the stockholders' meeting to vote on the Extension remains July 10, 2023. Stockholders who have previously submitted the ir proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders as of the Record Date can vote, even if they have subsequently sold their shares.

09:13 EDT Jupiter Wellness to begin production of Safety Shot in Q4 - Jupiter Wellness has engaged a well-established contract beverage manufacturer/packer with facilities across the United States to begin production of Safety Shot in Q4 2023. Recently acquired by Jupiter Wellness, Safety Shot, the world's first blood alcohol detox drink, will debut in a 12-ounce sleek can.

09:09 EDT Clear Secure expands LinkedIn ID verification to Canada - Clear (YOU) and Microsoft's (MSFT) LinkedIn platform are expanding their partnership by enabling LinkedIn members in Canada to verify their identity with Clear for free. From the LinkedIn app, a member can affirm their identity with the Clear Verified platform, and add a visible indicator to their LinkedIn profile showing the member's identity has been verified by Clear . Beginning this month, LinkedIn's 22 million Canada-based members will have the option to verify their identity with Clear in English or French. Earlier this year, Clear and LinkedIn launched free identity verification for LinkedIn's 206 million U.S.-based members.

09:07 EDT Huntington Ingalls receives order to build two REMUS 620 UUVs for NOAA - The National Oceanic and Atmospheric Administration, NOAA, recently ordered two REMUS 620 unmanned underwater vehicles, UUVs, from HII. The customized, medium-class UUVs will be built by HII's Mission Technologies division in partnership with W.S. Darley & Co. and delivered in 2024. "The REMUS 620 is the first medium-class UUV designed to accurately deliver this range of advanced above- and below-water effects at long range," said Duane Fotheringham, president of Mission Technologies' Unmanned Systems business group. "We are excited to build these vehicles for the U.S. government, supporting the mission of our long-term customer, NOAA." NOAA will use the REMUS 620 vehicles for higher-resolution mapping of the Gulf of Mexico and its effort to restore the seafloor habitats damaged by the 2010 Deepwater Horizon oil spill. The agency has previously used other REMUS models for habitat characterization, marine archeology and other ocean mapping and exploration activities.

09:04 EDT Heart Test Laboratories announces further expansion of AI patent portfolio - Heart Test Laboratories announces that it has been issued a notice of patent allowance from the European Patent Office. To date, HeartSciences has been granted or allowed 41 patents including 9 in the United States. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, "Millions of ECG's are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefit to healthcare providers and health systems around the world. Cardiovascular disease continues to rise and accounts for 20.5 million deaths, an estimated 1 in 3 of all deaths worldwide. HeartSciences MyoVista could play a significant role in heart health screening worldwide."

09:03 EDT Vita Coco expands social impact program to Brazil - The Vita Coco Company announced the expansion of its social impact program, The Vita Coco Project, to Brazil. The Vita Coco Project was founded in 2014 through the Company's Environmental and Social Initiative program to support and empower coconut sourcing communities. To date, The Vita Coco Project, through its local partners, has distributed more than 370,000 seedlings and trees, trained more than 1,000 farmers in regenerative agricultural practices and constructed 36 classrooms and schools in the Philippines and Sri Lanka. In the Philippines, farmers participating in the project have seen an 88% increase in their income. In partnership with Brazilian environmental nonprofit Apremavi, The Vita Coco Project will support the planting of trees in both urban communities and in forests nationwide. The reforestation efforts will protect habitats for some of Brazil's native species and drive the impact of the initiative beyond coconut farming.

09:02 EDT Bridg launches Rippl data, media network - Bridg announced the launch of Rippl, a data and media network, in order to unlock collaborative and profitable retail media partnerships for regional retailers and advertisers. Powered by Bridg's unique identity resolution technology, Rippl is built to amplify and enrich regional retailers' first party data so that advertisers can access a national footprint of individual shoppers characterized by both scale and enhanced insights. Rippl provides a single point of access to anonymized shopper profiles enriched with SKU-level data across retailers. Working with our campaign partner Universal Media, Rippl is designed to enable advertisers to leverage these unique insights, create tailored audiences and execute unified campaigns spanning multiple retailers. Advertisers can consistently and transparently measure the real impact on sales, aiming to deliver a new level of accountability to campaigns. Rippl's advantages are also intended to extend to retailers. Increased campaign investment, new monetization opportunities in both data and media, and refined synergies in partner collaboration encompassing trade and media spend, product innovation, and messaging are all part of Rippl's value proposition.

08:55 EDT Grid Dynamics partners with Blue Yonder - Grid Dynamics Holdings announced a partnership with Blue Yonder. This collaboration focuses on Blue Yonder's Commerce microservices and enables Grid Dynamics to significantly broaden its supply chain service offering by incorporating Blue Yonder's Order Management Services, along with Warehousing and Transportation solutions. This new partnership allows Grid Dynamics to efficiently deliver these supply chain offerings to clients at scale.

08:54 EDT ParaZero signs development agreement with Black Square - ParaZero Technologies announced its further expansion into the Latin American drone market with a new development agreement with Colombia-based drone OEM, Black Square, an industrial drone producer leader in the region that focuses on enterprise drone platforms. Black Square's decision to integrate ParaZero's patented parachute technology underscores the importance of safety in advanced drone operations.

08:51 EDT Fastly expands domains API and TLS capacity with Domainr acquisition - Fastly announced two major developments in its domain name API and Transport Layer Security capabilities: the acquisition of Domainr, an ICANN-accredited real-time domain availability API provider, as well as general availability of Certainly, Fastly's publicly-trusted TLS Certification Authority . These developments significantly advance Fastly's edge cloud platform as well as its mission to foster a global web infrastructure that is more accessible, trusted and secure. "Through the availability of Certainly and the acquisition of Domainr, we are continuing to empower our customers to own and control what they create, and how they create it - all backed by the most trusted and reliable domain availability and TLS experience possible," said Fastly CEO Todd Nightingale. "By offering these fundamental building blocks alongside our industry-leading content delivery network, Compute@Edge, and beyond, Fastly is proud to be an engine for the best builders and the best platforms on the internet."

08:50 EDT IperionX to produce titanium plate for testing by Lockheed Martin - IperionX Limited (IPX) has agreed to an order with Lockheed Martin (LMT) for the delivery of titanium plate components produced using IperionX's U.S. manufactured titanium. IperionX's advanced titanium production technologies have the potential to provide a lower cost and more sustainable U.S. domestic supply chain for titanium raw material. "Reducing the cost of titanium components will mean broader use of this material to increase the performance of our products," said Brian Rosenberger, Lockheed Martin senior fellow for Additive Manufacturing Processes and Materials. "With this order, Lockheed Martin will perform an initial evaluation of the material quality and mechanical performance of IperionX's titanium plate material." The titanium plate components for Lockheed Martin will be manufactured with powder metallurgy production methods and IperionX's advanced titanium angular powder. To deliver higher performance and durability, IperionX will also employ its patented Hydrogen Sintering and Phase Transformation technologies, a cutting-edge technique to enhance the microstructure of titanium parts to deliver strength and fatigue properties that are comparable to wrought titanium alloys.

08:40 EDT Bridgeline renews agreement with US printing, marketing company - Bridgeline Digital announced that a leading US printing and marketing company has renewed its enterprise-level agreement with Bridgeline's online franchise solution, TruPresence. The printing powerhouse has expanded its enterprise contract to $94k over a 12-month period to continue to leverage the TruPresence platform to drive its online reach across its 300+ local business centers."Our ongoing partnership with one of the largest national printing companies highlights their trust in TruPresence to drive their digital growth," said Ari Kahn, Bridgeline Digital's CEO.

08:38 EDT Jaguar Health's Napo completes last patient visit for Phase 3 OnTarget trial - Napo Pharmaceuticals announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. This trial is studying an indication Napo also refers to as preventive treatment of chemotherapy-induced overactive bowel - which includes symptoms such as chronic debilitating diarrhea (loose and/or watery stools), urgency, and bowel incontinence. Top-line results for the primary endpoint in this trial are expected the last week of October 2023.

08:36 EDT Qualigen Therapeutics partners with TD2 for Phase 1 development of QN-302 - Qualigen Therapeutics is partnering with Translational Drug Development as the contract research organization to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors. TD2 is a precision oncology drug development organization integrating preclinical, clinical, and regulatory expertise and providing expert drug development services, including the design and execution of oncology clinical trials. TD2 has a proven track record of obtaining IND clearances and managing complex trial designs, including recruitment for Orphan diseases, to accomplish first patient dosing as quickly as possible. Qualigen Therapeutics secured exclusive worldwide rights to QN-302 in January 2022 from University College London. QN-302 was invented and developed by Professor Stephen Neidle and his team from the UCL School of Pharmacy, one of the top ten pharmacy and pharmacology research institutions in the world. Professor Neidle has a distinguished 30+ year history in nucleic acid research and drug design with over 500 published papers and 14 patents and has been a member of Qualigen's QN-302 Scientific Advisory Board since February 2022. Qualigen plans to initiate activation of the first Phase 1 clinical trial site and enroll the first patient in the Phase 1 dose escalation clinical study later this year. Qualigen will enroll patients with advanced or metastatic solid tumors who have failed prior therapy.

08:35 EDT Regeneron receives EMA filing acceptance for treatment of R/R FL - Regeneron Pharmaceuticals announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, MAA, for odronextamab to treat adult patients with relapsed/refractory follicular lymphoma, FL, or R/R diffuse large B-cell lymphoma, who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for FL and DLBCL. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The MAA is supported by data from a Phase 1 and pivotal Phase 2 trial investigating odronextamab in FL and DLBCL, which were last presented at the 64th American Society of Hematology Annual Meeting.

08:34 EDT Nemaura Medical announces SFDA approval of sugarBEAT - Nemaura Medical announced SFDA approval of sugarBEAT, its non-invasive wearable glucose sensor. The news comes following over a year of liaisons with the SFDA through TPMENA, the Company's licensee in the Middle East, and is seen as a major breakthrough in product commercialisation in the largest territory in the Middle East, and a region with one of the world's highest diabetes prevalence rates. Nemaura Medical is in advanced discussions to play a role in the region with its superior sensor technology, and diabetes and metabolic health management programs.

08:33 EDT OSI Systems awarded contract valued at approximately $14M - OSI Systems announced that its Security division received a contract award valued at approximately $14M from a South America based customer to provide multiple units of its Eagle P60 high-energy, drive-through cargo and vehicle inspection system, VM250 radiation portal monitor, and MINI Z handheld backscatters devices, among others. The Company plans to fully support the integration with Certscan, offer installation assistance, provide local operator training, and deliver multi-year service and maintenance. OSI Systems' Chairman and CEO, Deepak Chopra, commented, "We are proud to receive this award and look forward to supporting this customer in its security initiatives. Leveraging our broad portfolio, we can optimize our solution offering to meet the vital security requirements for cargo and vehicle checkpoints in an efficient manner."

08:23 EDT CVS Health falls 7% after WSJ reports Blue Shield of CA dropping Caremark PBM - In pre-market trading, shares of CVS are down 7% to $67.51.

08:19 EDT Pieris Pharmaceuticals achieves milestone payment from Boston Pharmaceuticals - Pieris Pharmaceuticals announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored phase 1/2 study of BOS-342, a 4-1BB/GPC3 immuno-oncology antibody-Anticalin fusion bispecific protein, which was discovered by Pieris and licensed to Boston Pharmaceuticals and designed to provide a potent costimulatory bridge to exert tumor killing activity through the recruitment of T-cells. The open-label phase 1/2 study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BOS-342. The Phase 1 dose escalation portion of the study is expected to enroll adults with hepatocellular carcinoma that progressed on at least one prior treatment and establish a recommended Phase 2 dose. If pursued, the Phase 2 portion of the study will evaluate efficacy, as measured by overall response rate. The study is funded and conducted by Boston Pharmaceuticals, who exclusively licensed worldwide rights to BOS-342 in April 2021. In addition to the milestone announced today, Pieris could potentially be entitled to receive up to approximately $350 million in development, regulatory and sales-based milestone payments, and tiered royalties on sales of BOS-342.

08:15 EDT Steven Boal issues second open letter to Quotient board - Steven Boal, who control in excess of 10% of the outstanding common stock of Quotient Technology, issued the following open letter to the Board of Directors of Quotient as a follow up to our letter of July 31, 2023: "Considering recent disclosures by Quotient, we write to express our continuing opposition to the Companies' proposed merger and proposed executive compensation plan for the reasons below: We view the proposed Merger as a rushed sweetheart deal that puts leadership's interests ahead of shareholders' best interests. If the current terms and structure remain intact, we intend to do everything in our power to oppose the transaction. The disclosed information references the valuation calculation used by the bankers hired by Quotient, Houlihan Lokey, as a Discounted Cash Flow using Quotient's 2025 financial projections. We find it confusing at best that a three year DCF was used to value Quotient when convention is to use 5 and 10-year DCF and in no recent cases that we can find, has there been anything less than a 4-year DCF for the same purpose. We ask that the Board publicly share the rationale and minutes from any discussions surrounding the choice of the shortened 3-year DCF that Houlihan Lokey used to value Quotient.The original indication of interest by Charlesbank/Neptune was $4.50 - $5.50 per share, and another interested party indicated an initial interest of $4.50 per share. We ask that the board share with stockholders what specific findings led to the eventual price falling below the bottom end of the range, given the positive public cash flow statements made recently by the Quotient CEO at an investor conference. We also analyzed Quotient's most recently released quarterly results, and we believe that on a combined basis, Quotient will generate between $70-$80 million of free cash flow in the first full year post-merger, given the expected redundancies in sales, operations, finance and legal teams. We were not surprised to see that stockholders voted AGAINST the 2023 equity incentive plan at Quotient's recent Annual Stockholder Meeting. The vote AGAINST is consistent with the negative feedback we have received in dialog with many of Quotient's stockholders regarding the process and outcome of the merger announcement. We understand that the Quotient Board has received more than one letter from large stockholders expressing frustration and legal concerns about the process. In closing, we strongly believe that given the above, shareholders should vote AGAINST the proposed merger unless the terms materially improve. We reiterate that as of August 3rd, 2023, and thanks to the cooperation agreement with Engaged Capital, Quotient has a completely reconstituted Board of Directors. In our view, this board has the experience necessary to protect stockholders' interests and run an unbiased and comprehensive review of strategic alternatives, including recruiting competent leadership to capitalize on the forecasted strong cashflows to enhance the current product and partnership portfolio."

08:13 EDT Xwell extends collaboration with CDC, Prevention's traveler-based surveillance - XWELL announced that they have renewed their support for the Centers for Disease Control and Prevention's Traveler-based Genomic Surveillance program through a new contract awarded August 12 for approximately $16 million. The innovative collaboration between CDC, XpresCheck and Concentric by Ginkgo Bioworks will continue for another year, expanding bio-surveillance capabilities across major U.S. airports. "Through the renewed investment in this initiative, we and our partners are continuing to play an important role in U.S. biosecurity through its two major goals; early detection of new SARS-CoV-2 variants and other pathogens and by filling the gaps in global bio-surveillance," stated Ezra Ernst, Chief Executive Officer of XpresCheck. "With CDC and Concentric by Ginkgo Bioworks, we are providing public health officials with timely insights into pathogen evolution as well as peace of mind to travelers. We have learned that people are eager to protect themselves, their communities and their global neighbors, and TGS facilitates this."

08:11 EDT Kronos Bio announces departure of CFO, Head of Corporate Development Al-Wakeel - Kronos Bio announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.

08:10 EDT GameSquare announces success of brand campaigns - GameSquare Holdings announced the success of four substantial contracts to build and develop marketing campaigns surrounding custom worlds for brands in popular gaming titles such as Fortnite and Roblox, including two recent wins with prominent blue-chip global brands. These contracts highlight growing demand for large brands to engage with gaming audiences by creating custom gaming worlds. The successful campaigns reflect GameSquare's ability to create a seamless bridge between brands and gamers by offering a unique platform for interactive brand experiences in the digital world.

08:09 EDT PetVivo receives notice of allowance from USPTO - PetVivo Holdings announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company's proprietary biocompatible protein-based particles. The broad scope of the issued claims in this patent, entitled "Biocompatible Protein-Based Particles and Methods Thereof" provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo's signature product, Spryng with OsteoCushion Technology. With the imminent patent issuance by the USPTO, PetVivo's intellectual property portfolio has grown to twenty allowed patents, ten of which are United States patents.

08:07 EDT Discover considering internal, external candidates for new CEO - The company says it has retained an executive search firm to find a new CEO. Comments taken from the company's business update conference call.

08:07 EDT Trust Stamp receives notice of new patent issuance in U.S. - Trust Stamp announces that on August 15, 2023, Patent # 11,729,158 entitled "Systems and Methods for Identity Authentication via Third Party Accounts" was issued to the Company by the US Patent and Trademark Offices. This patent is the eighteenth issued to the company in addition to which the company has an additional thirteen patent applications pending.

08:06 EDT ZimVie expands development cooperation agreement with Brainlab - ZimVie announced it has expanded its cooperation agreement with Brainlab. ZimVie and Brainlab have started a joint project to achieve compatibility between ZimVie's Vital and Virage fixation systems and Brainlab spine and trauma navigation technologies, which help surgeons plan and execute spinal procedures, accurately place pedicle screws, and minimize radiation exposure. In addition, ZimVie will co-market the Brainlab spine and trauma navigation technologies alongside its existing spine implant solutions globally. "We are excited to partner with Brainlab to bring into the operating room differentiated technology aiming at enhancing workflow and accuracy for surgeons and staff," said Vafa Jamali, President and Chief Executive Officer of ZimVie. "We have been focused on expanding our portfolio with enabling technology to drive greater adoption across our spine portfolio. Our common interest in delivering clinical and economic value to our customers and patients aligns perfectly with ZimVie's strategic initiatives."

08:05 EDT Nuvectis Pharma announces ODD granted by FDA to NXP800 - Nuvectis Pharma announced that NXP800 was granted Orphan Drug Designation, ODD, by the United States Food and Drug Administration, FDA, for the treatment of cholangiocarcinoma. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are pleased to have received this designation from the FDA for NXP800, which emphasizes the need for new, innovative therapies for the treatment of cholangiocarcinoma, a deadly malignancy with only limited treatment options available. NXP800 is an oral small molecule with a novel mechanism of action that has demonstrated robust activity in several preclinical cancer models, including ARID1a-mutated ovarian, endometrial and gastric carcinomas, as well as cholangiocarcinoma. The clinical activity of NXP800 is currently being evaluated in a Phase 1b clinical trial in patients with platinum resistant, ARID1a-mutated ovarian carcinoma, with additional diseases planned for clinical investigations. This orphan drug designation is an important milestone in our journey toward our mission of developing NXP800 for the treatment of serious conditions of unmet medical need in oncology."

08:03 EDT Leidos selected by U.S. Navy to operate and sustain unmanned vessels - Leidos was recently awarded a new task order by Naval Sea Systems Command to manage, operate and maintain the U.S. Navy's Overlord and medium unmanned surface vessels. The single-award task order has a one-year base period of performance and two one-year options. The task order has a maximum value of approximately $95M if all options are exercised. Leidos has delivered four operational medium-sized USVs currently in the Navy's fleet: Ranger, Mariner, Sea Hunter, and Seahawk.

08:01 EDT IBM, Microsoft expand generative AI collaboration - IBM (IBM) is expanding its collaboration with Microsoft (MSFT) to help joint clients accelerate the deployment of generative AI - and deliver a new offering that will provide clients with the expertise and technology they need to innovate their business processes and scale generative AI effectively. IBM Consulting, in collaboration with Microsoft, will focus on helping clients to implement and scale Azure OpenAI Service. The new IBM Consulting Azure OpenAI Service offering, which is available on Azure Marketplace, is a fully managed AI service that allows developers and data scientists to apply powerful large language models, including their GPT and Codex series. It aims to help businesses define an adoption strategy and an initial set of specific and value-add generative AI use cases.

07:38 EDT Ocean Power unveils achievement in field of autonomous maritime technology - Ocean Power Technologies announces an achievement in the field of autonomous maritime technology. During a presentation by OPT's VP of Global Sales and Marketing, Matt Burdyny, at the 10th Annual Maritime Security West event, OPT revealed a groundbreaking milestone: the successful demonstration of the Wave Adaptive Modular Vessel attaching itself remotely to a buoy and establishing a connection that will enable charging. This significant achievement was unveiled through a video, captured during on-water trials conducted earlier this month. "Our successful demonstration of a WAM-V remotely attaching itself to a buoy that will enable establishing a charging connection is a defining moment for OPT and the maritime technology sector as a whole," stated Matt Burdyny after the presentation. "This achievement underscores our commitment to reshaping autonomous maritime operations by leveraging renewable energy for sustainable charging solutions."

07:35 EDT Vivid Seats selected as an official Proud Partner of Los Angeles Chargers - Vivid Seats announced a fan experience partnership with the Los Angeles Chargers as an official Proud Partner. As part of the partnership, Vivid Seats customers will now have exclusive access to the Perch Suites at SoFi Stadium, home of the Los Angeles Chargers. "We are thrilled to be a Proud Partner of the Los Angeles Chargers, enabling access to one of the most unique experiences in Southern California sports," said Geoff Lester, Chief Commercial Officer at Vivid Seats. "As we continue to differentiate the live event experience, alongside the Chargers, we are providing our customers with a best-in-class hospitality and entertainment experience, ensuring an unforgettable Chargers gameday."

07:32 EDT Canopy Growth to sell Hershey Drive facility to Hershey Canada for C$53M - Canopy Growth announced that it has entered into an agreement to sell its Hershey Drive facility in Smiths Falls, Ontario, as part of the company's transformation to a simplified, asset-light operating model. Canopy Growth will retain its Smiths Falls-based post-harvest manufacturing facility. Pursuant to the terms of the Agreement, the Facility will be sold to Hershey Canada for cash consideration of approximately C$53M. The completion of the Transaction is subject to customary closing conditions. Upon the completion of the Transaction, Canopy Growth will have sold a total of seven properties for an aggregate gross amount of approximately C$155M since April 1, 2023. Net proceeds received from the sale of the Facility will be used primarily to pay down the company's senior secured credit facility.

07:23 EDT Vox Royalty provides project updates across gold royalty portfolio - Vox Royalty (VOXR) provides recent development and exploration updates from royalty operating partners Genesis Minerals, Alamos Gold (AGI), Black Cat Syndicate, Northern Star Resources (NESRF) and Strickland Metals. Riaan Esterhuizen, EVP Australia stated: "We are very excited to share recent gold operator developments and initial royalty revenue from the Kookynie royalty, linked to the release of maiden reserves at the Puzzle North gold deposit. This initial royalty revenue of ~A$2M represents an approximate 15x return on the A$150k invested in the Kookynie royalty back in 2020, with further revenue expected post commencement of mining by Genesis. Further engineering study progress at Lynn Lake and Bulong continue to underpin Vox management confidence in medium-term growth prospects for our royalty portfolio." Genesis released Pre-Feasibility Stage level assumptions and maiden reserves for the Puzzle Group gold deposits in Western Australia triggering maiden royalty revenue of approximately A$2M, to be recorded as Q3 2023 royalty revenue and payable within 45 days of quarter end; Alamos released an updated feasibility study on the Lynn Lake Gold Project in Manitoba, Canada; Black Cat released an updated engineering study for the Kal East Project which includes the Bulong gold royalty; and Northern Star acquired the Millrose exploration-stage gold project from Strickland for A$67 million.

07:18 EDT Tilray's Good Supply launches JUICED infused pre-rolls - Tilray Brands announced the launch of the new JUICED infused pre-rolls by its Canadian cannabis brand, Good Supply, bringing the brand's pre-roll collection to new heights. The company said, "Introducing Good Supply Juiced a new series of bold and fruity infused pre-rolls and blunts, formulated for on-the-go experiences to add to consumers' days. Its jam-packed flavours and smooth smoking experience are produced from a combination of strain-specific flower and the fruit-flavoured extract of Good Supply's best-selling vapes. The Good Supply JUICED sub-brand will feature several flavours and formats, including JUICED single flavour multi-packs, JUICED infused blunts, and the JUICED Discovery Pack, a rotating multi-pack offering through which a new series of flavours will be introduced every 6 months."

07:15 EDT Ayr Wellness expects to generate revenue, Adjusted EBITDA growth in 2H23 - The company said, "The Company remains committed to its financial health and is positioning itself to achieve sustainable long-term growth and profitability across all markets of operation. AYR expects to generate revenue and Adjusted EBITDA growth in the second half of 2023 and into 2024 and to generate positive GAAP cash flow from operations for the calendar year 2023."

07:11 EDT Canadian Solar to deliver 1,200 MWh in energy storage solutions in Arizona - Canadian Solar announced that e-STORAGE, part of its majority-owned subsidiary CSI Solar, will deliver 1,200 MWh of energy storage solutions to Recurrent Energy's Papago Storage project in Arizona. Recurrent Energy, a wholly-owned subsidiary of Canadian Solar, is expected to begin construction on Papago Storage in Q3 2024. Once operational, Papago Storage will be one of the world's largest standalone energy storage projects and the largest standalone energy storage project in Arizona. The contract is subject to final approval from the CSI Solar board of directors and shareholders.

07:07 EDT Modine Manufacturing partners with TMS Johnson for school-focused HVAC products - Modine is partnering with TMS Johnson to help empower school leaders and facility managers to provide indoor air quality solutions by offering a full range of school-focused HVAC products. As part of the partnership, TMS Johnson will represent Airedale in Minnesota and Western Wisconsin. For over 50 years, TMS Johnson has supplied HVAC equipment to the contracting and engineering communities of Minnesota and Western Wisconsin. With the goal of being a full-service supplier of HVAC equipment, the company now adds Airedale's line of K-12 school HVAC solutions to its manufacturers list.

07:06 EDT Mullen Automotive starts $25M stock buyback program - Mullen Automotive announces the start of the Company's $25 million stock buyback program with the repurchase of 3.7 million shares of common stock, which started on Aug. 16, 2023, and can continue through Dec. 31, 2023, for an aggregate of $3,626,000. David Michery, CEO and chairman of Mullen also purchased 102,040 shares in the open market on Aug. 16, 2023, at a price of $0.9842 per share. The Company is committed to taking all available measures to regain compliance with the NASDAQ minimum $1.00 bid price requirement. "We believe that our stock is undervalued. The Company has begun production of our Class 3 EV with deliveries pending to customers and a strong balance sheet allowing us to execute on our business plan," said David Michery, CEO and chairman of Mullen.

07:05 EDT Tecnoglass relocates global headquarters to United States - Tecnoglass announced the relocation of its global headquarters to Miami, Florida from Barranquilla, Colombia. The relocation is effective immediately. This strategic move is aimed to further bolster the Company's strong market presence and continued growth in the United States, where it sells the majority of its innovative architectural high-end window, glass and aluminum products. Jose Manuel Daes, Chief Executive Officer of Tecnoglass, commented, "Becoming a U.S. based company is an exciting milestone for our Company. Our successful record of sustainable growth in the U.S. has already helped to cement Tecnoglass as a U.S.-centric company. The decision to relocate our global headquarters to Miami is aligned with this growth and underscores our commitment to further strengthening our customer relationships, streamlining administrative functions and enhancing our operational efficiency."

07:04 EDT Selecta Biosciences expects cash to fund operations into 2027 - Cash Position: Selecta had $115.0 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2023, as compared to cash, cash equivalents, restricted cash, and marketable securities of $136.2 million as of December 31, 2022. Selecta believes that following the capital efficiencies expected to be realized through its strategic reprioritization and following receipt of the next anticipated milestone payment related to SEL-212 development activities, its available cash, cash equivalents, restricted cash, and marketable securities will be sufficient to meet its operating requirements into 2027.

06:52 EDT Piedmont Lithium to increase stake in Atlantic Lithium's Ewoyaa Project - Piedmont Lithium announced the company will increase its stake in Atlantic Lithium Limited's Ewoyaa Lithium Project as part of a staged investment agreement to earn a 50% equity interest in Atlantic Lithium's Ghanaian lithium portfolio. Under the terms of the project agreement with Atlantic Lithium, Piedmont has exercised its option to acquire a 22.5% interest in Ewoyaa, having funded the completion of the Project's definitive feasibility study. Piedmont also plans to provide a further $70M toward Ewoyaa development capital to acquire an additional 27.5% interest in the Project. Piedmont expects to share the remaining Project capital costs equally with Atlantic Lithium for a total Piedmont commitment of approximately $128M toward the total estimated $185M Project capital costs. The company's additional funding remains subject to the receipt of final government and regulatory approvals for the Project. Piedmont expects to be able to fund its contributions toward Project development through proceeds from the sale of lithium concentrate from its offtake agreement with North American Lithium. The company is entitled to purchase 50% of lithium concentrate production at Ewoyaa on a market-based pricing mechanism for the life of the mine. This offtake is being planned as feedstock for the company's proposed, 30,000-metric-ton-per-year lithium hydroxide conversion facility in Tennessee.

06:35 EDT Parsons selected by NY State Department of Transportation for Interstate 787 - Parsons was selected by the New York State Department of Transportation - NYSDOT - to complete a Planning and Environment Linkages study for the potential reconfiguration of the Interstate 787 corridor in the greater Albany area. This study will be the first step to identify a range of transformative infrastructure improvement alternatives that may be advanced for further engineering and environmental analyses. Built in the 1960's, I-787 is one of many highways across the United States that is being reimagined.

06:33 EDT KVH Industries and Intelsat renew three-year satellite partnership - KVH Industries completed a three-year renewal of its satellite services contract with Intelsat. The renewal includes increased network capacity, the flexibility to support future bandwidth adjustments, and reduced service costs that will enable KVH to offer more competitive airtime rates for mariners. In addition to KVH's terminals, the new KVH ONE OpenNet Program enables vessels with non-KVH VSAT antennas global VSAT coverage from KVH.

06:11 EDT American Strategic Investment Co. sells Hit Factory property for $4.5M - American Strategic Investment has signed a definitive purchase and sale agreement to sell a property it owns at 421 W. 54th Street, the "Hit Factory, for $4.5M. The sale is expected to close in Q4. Net proceeds from the sale of the property, which is unencumbered, will be available for general corporate purposes.

06:10 EDT Stellantis invests $100M in CTR to develop U.S. geothermal lithium production - Stellantis and Controlled Thermal Resources, or CTR, announced a major investment of over $100M from Stellantis to advance the development of CTR's Hell's Kitchen project, the world's largest geothermal lithium project with a total resource capacity to produce up to 300,000 metric tons of lithium carbonate equivalent each year. Lithium produced at Hell's Kitchen will support Stellantis vehicles' BEV eligibility for consumer incentives under the U.S. Inflation Reduction Act. Additionally, the companies expanded the initial supply agreement, which now calls for CTR to supply up to 65,000 metric tons of battery-grade lithium hydroxide monohydrate each year over a 10-year contract term. This new agreement incorporates the original lithium supply agreement signed by both companies in June 2022 for up to 25,000 metric tons of LHM per year. Stellantis is on track to become a carbon net zero corporation by 2038, all scopes included, with single-digit percentage compensation of remaining emissions. CTR is scheduled to commence battery-grade lithium hydroxide monohydrate supply for Stellantis in 2027. The company expects to create 480 construction jobs through comprehensive project labor agreements and upward of 940 direct project jobs when the resource is fully developed.

05:26 EDT James Hardie CFO Jason Miele steps down, Rachel Wilson succeeds - James Hardie (JHX) announced the appointment of Rachel Wilson as CFO, effective immediately. As a member of the global executive team, Wilson will report directly to CEO Aaron Erter. Wilson was appointed after Jason Miele stepped down as CFO. Miele will remain with the company for three months as an advisor to the CEO for special projects and will thereafter depart the organization. Most recently, Wilson served as executive VP, CFO and treasurer at R1 RCM (RCM).

05:20 EDT AbbVie announces European Commission approval for Aquipta - AbbVie announced that the European Commission has approved Aquipta for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes Aquipta the first and only once-daily oral calcitonin gene-related peptide receptor antagonist treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

05:08 EDT A-Gas, KKR sell majority stake to TPG Rise Climate - A-Gas announced that its owners, including majority owner KKR (KKR), have entered into a definitive agreement to sell a majority stake in the company to TPG Rise Climate, the dedicated climate investing strategy of TPG's (TPG) global impact investing platform, TPG Rise. KKR will remain a significant minority shareholder in the business, continuing to work in collaboration with TPG Rise Climate and the A-Gas Leadership Team. The transaction is expected to be completed by the end of 2023, subject to customary closing conditions, including certain regulatory approvals. Additional terms of the transaction were not disclosed.